Quidel Corp
NASDAQ:QDEL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Quidel Corp
Free Cash Flow
Quidel Corp
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Quidel Corp
NASDAQ:QDEL
|
Free Cash Flow
-$83m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Free Cash Flow
$257m
|
CAGR 3-Years
26%
|
CAGR 5-Years
17%
|
CAGR 10-Years
25%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Free Cash Flow
$82.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-8%
|
CAGR 10-Years
7%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Free Cash Flow
$490.8m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
10%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Free Cash Flow
$354.1m
|
CAGR 3-Years
10%
|
CAGR 5-Years
146%
|
CAGR 10-Years
45%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Free Cash Flow
$212.5m
|
CAGR 3-Years
45%
|
CAGR 5-Years
13%
|
CAGR 10-Years
29%
|
|
Quidel Corp
Glance View
Quidel Corporation, a player in the diagnostic healthcare industry, has steadily navigated the labyrinth of medical innovation, carving out a niche in rapid diagnostic testing. Born out of a mission to streamline the process of disease detection, Quidel has leveraged biotechnology to develop fast, reliable diagnostic solutions that address widespread health issues. This company’s arsenal includes tests for infectious diseases, reproductive health, and autoimmune disorders—each meticulously designed to expedite the diagnostic process while maintaining a stringent commitment to accuracy. By fostering partnerships with healthcare providers and aligning with technological advancements, Quidel has positioned itself as indispensable in the clinic setting, where swift decision-making can significantly impact patient care. At the heart of Quidel's business model is its focus on providing tangible value to both healthcare professionals and patients. The company generates revenue primarily through the sale of its diagnostic products, which are utilized in settings ranging from small clinics to large hospital networks. Quidel's innovative platforms, like the Sofia and Solana systems, are lauded for their efficiency and ease of use, attributes that resonate particularly well in medical environments under pressure to deliver fast and effective results. By effectively converting scientific expertise into practical and user-friendly applications, Quidel not only enhances patient outcomes but also fortifies its financial standing within the competitive landscape of medical diagnostics.
See Also
What is Quidel Corp's Free Cash Flow?
Free Cash Flow
-83m
USD
Based on the financial report for Dec 28, 2025, Quidel Corp's Free Cash Flow amounts to -83m USD.
What is Quidel Corp's Free Cash Flow growth rate?
Free Cash Flow CAGR 1Y
26%
Over the last year, the Free Cash Flow growth was 26%.